Olatoyosi Odenike to Benzimidazoles
This is a "connection" page, showing publications Olatoyosi Odenike has written about Benzimidazoles.
Connection Strength
0.587
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.431
-
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 02 26; 3(4):508-518.
Score: 0.156